Clinical Trials
8 trialsNCT06710756 2026-06-05
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT05732831 2026-04-21
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT05944237 2025-06-08
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Phase 1/2 Recruiting
NCT01291420 2024-12-09
Dendritic Cell Vaccination for Patients with Solid Tumors
University Hospital, Antwerp
Phase 1/2 Completed
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated